Trial Profile
A Retrospective study to compare the safety of Subcutaneous Immunotherapy, Omalizumab and Combination Therapy in Children with Allergic Asthma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Mar 2018
Price :
$35
*
At a glance
- Drugs Immunotherapies (Primary) ; Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- 23 Mar 2018 New trial record
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology